Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05712694
Other study ID # POLARIS2022-001
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 29, 2023
Est. completion date December 30, 2027

Study information

Verified date December 2023
Source Polaris Group
Contact Mirla Langlois
Phone 858-452-6688
Email mlanglois@polarispharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.


Description:

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 30, 2027
Est. primary completion date December 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - A subject will be eligible for study participation if he/she meets the following criteria: 1. Histologically or cytologically confirmed, grade 2 or 3, LMS STS that would be standardly treated with Gem or GemDoc. 2. Determination of LMS subtype: uterine or non-uterine. 3. Measurable disease per RECIST 1.1 (Appendix A), defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with CT scan, as = 20 mm by chest x-ray, or = 10 mm with calipers by clinical exam. 4. Previous treatment with up to 2 systemic regimens, including at least 1 systemic regimen containing doxorubicin. 5. Treatment > one year ago in the adjuvant/neoadjuvant setting with Gem or Doc is allowed. 6. Age >18 years. 7. Eastern Cooperative Oncology Group (ECOG) performance status of < 1 at enrollment (Appendix B). 8. Leukocytes = 3,000/mcL. 9. Absolute neutrophil count = 1,500/mcL. 10. Platelets = 100,000/mcL. 11. Total bilirubin = 2 x ULN. (= 3 x ULN for potential subjects with Gilbert's Disease) 12. AST(SGOT)/ALT(SGPT) = 3 x ULN (or = 5 x ULN if liver metastases are present) 13. Creatinine clearance = 60 mL/min (by Cockcroft-Gault equation). 14. Serum uric acid = 8 mg/dL (with or without medication control). 15. QTc interval range from 350 to 450 ms for adult men and from 360 to 460 ms for adult women. 16. Subjects and their partners must be asked to use appropriate contraception. They must agree to use 2 forms of contraception or agree to refrain from intercourse for the duration of the study and for 35 days after the last dose of ADI-PEG 20 or for at least 3 months (male subjects) or 6 months (female subjects) after treatment with gemcitabine, whichever is the longer duration. 17. Ability to understand and willingness to sign the informed consent form. 18. No concurrent investigational drug studies are allowed. Exclusion Criteria: - A subject will not be eligible for study participation if he/she meets any of the exclusion criteria: 1. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the Investigator will not affect subject outcome in the setting of current diagnosis. 2. Currently receiving other investigational agents. 3. Prior treatment with ADI-PEG 20, Gem or Doc. Patients treated > one year ago in the adjuvant/neoadjuvant setting with Gem or Doc are allowed to be enrolled. 4. Known brain metastases. Such patients must be excluded from this trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. 5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, Gem, Doc, polysorbate 80, pegylated compounds, or other agents used in this study. 6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 7. History of seizure disorder not related to underlying cancer. 8. Grade 2 or higher neuropathy. 9. Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. 10. Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study treatment. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ADI PEG20
Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
Other:
Placebo
Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)

Locations

Country Name City State
Canada McGill University Health Centre (Quebec) Montréal Quebec
Canada UHN - Princess Margaret Cancer Center (Ontario) Toronto Ontario
Taiwan National Taiwan University Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei
United States University of Michigan Ann Arbor Michigan
United States University of Colorado Cancer Center/ CU Anschutz Medical Campus Aurora Colorado
United States Northwestern Chicago Illinois
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States Ohio State University Wexner Medical Center/ The James Cancer Hospital and Solove Research Institute Columbus Ohio
United States Duke Cancer Institute Durham North Carolina
United States Indiana University Indianapolis Indiana
United States University of Iowa Iowa City Iowa
United States University of Miami/ Sylvester Comprehensive Cancer Center Miami Florida
United States UPenn (Abramson Cancer Center, Pennsylvania Hospital) Philadelphia Pennsylvania
United States Washington University School of Medicine - Siteman Cancer Center Saint Louis Missouri
United States Wake Forest Baptist (Atrium Health) Salem North Carolina
United States Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Polaris Group

Countries where clinical trial is conducted

United States,  Canada,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary End Point of PFS The primary objective is to compare the primary endpoint of PFS in subjects treated with the arginine degrading enzyme ADI-PEG 20 plus Gem and Doc (ADIGemDoc) or PBO plus Gem and Doc (PBOGemDoc) in the 2nd or 3rd line setting using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by blinded independent central review committee (BICR) Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Secondary Secondary End Point of ORR (CR+PR) The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to:
Objective response rate (ORR) (complete response [CR] + partial response [PR]) The secondary endpoint of ORR will be assessed by BICR using RECIST 1.1 and tested using a CMH test stratified by the stratification factors used during the randomization based on the ITT population.
Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Secondary Secondary End Point of Overall Survival (OS) The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to:
OS
The secondary endpoint of OS will be tested using a log-rank test stratified by the stratification factors used during the randomization based on the ITT population. A stratified Cox model will be used to estimate HR and 95% CI, and KM curves will be used to estimate OS median and 95% CI.
Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Secondary Secondary End Point of Safety and Tolerability All clinically significant abnormalities and deteriorations will be followed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE V5). Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
See also
  Status Clinical Trial Phase
Recruiting NCT02910895 - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) N/A
Recruiting NCT05621668 - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Phase 1
Active, not recruiting NCT04032964 - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS Phase 1
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT01650077 - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02204111 - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn NCT01663090 - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas N/A
Completed NCT01259375 - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Phase 2
Completed NCT01440088 - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Phase 3
Completed NCT01106872 - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Phase 1
Recruiting NCT00753727 - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma Phase 1/Phase 2
Terminated NCT00755261 - Phase II Study of Doxorubicin and Avastin® in Sarcoma. Phase 2
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT00611078 - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study N/A
Completed NCT03452644 - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated NCT03520959 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) Phase 3